PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Václav HEJRET and Michal ŠMÍDA. The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. In Biomania, Brno. 2019.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia
Authors PESCHELOVÁ, Helena (203 Czech Republic, belonging to the institution), Veronika KOZLOVÁ (203 Czech Republic, belonging to the institution), Václav HEJRET (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, guarantor, belonging to the institution).
Edition Biomania, Brno, 2019.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30204 Oncology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14740/19:00112810
Organization unit Central European Institute of Technology
Keywords in English CRISPR/Cas9; chronic lymphocytic leukemia
Tags rivok
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 26/3/2020 13:37.
Abstract
CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia, CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 25/7/2024 18:28